503601-25-0

Basic information

• Product Name: Ethyl 2-(morpholin-2-yl)acetate
• Synonyms: MORPHOLIN-2-YL-ACETIC ACID ETHYL ESTER;ETHYL 2-(MORPHOLIN-2-YL)ACETATE;ethyl morpholin-2-ylacetate;2-Morpholineacetic acid ethyl ester HCl
• CAS NO: 503601-25-0
• Molecular Formula: C₈H₁₅NO₃
• Molecular Weight: 173.21
• Product Categories: API intermediates
• Mol File: 503601-25-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 244.4±15.0 °C(Predicted)
• Appearance: /
• Density: 1.033±0.06 g/cm3(Predicted)
• Refractive Index: 1.435
• Storage Temp.: 2-8°C(protect from light)
• PKA: 8.53±0.40(Predicted)
• CAS DataBase Reference: Ethyl 2-(morpholin-2-yl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 2-(morpholin-2-yl)acetate(503601-25-0)
• EPA Substance Registry System: Ethyl 2-(morpholin-2-yl)acetate(503601-25-0)

Safety Data

• Hazardous Substances Data: 503601-25-0(Hazardous Substances Data)

Usage

General Description

Ethyl 2-(morpholin-2-yl)acetate is a chemical compound that is used in various pharmaceutical and industrial applications. It is formed by the condensation of ethyl acetoacetate and morpholine. Ethyl 2-(morpholin-2-yl)acetate is commonly used as a building block in the synthesis of various pharmaceutical drugs and in the production of agrochemicals and specialty chemicals. Ethyl 2-(morpholin-2-yl)acetate is known for its ability to act as a chelating agent, as well as for its potential as a drug intermediate. It is also utilized as a solvent in certain chemical reactions and processes. This chemical has a variety of potential uses in the pharmaceutical and chemical industries and is valued for its versatility and usefulness in these applications.

InChI:InChI=1/C8H15NO3/c1-2-11-8(10)5-7-6-9-3-4-12-7/h7,9H,2-6H2,1H3

Upstream product

• 73933-19-4 ethyl 4-(phenylmethyl)-2-morpholineacetate 
• 37746-78-4 4-bromo-trans-crotonic acid ethyl ester 

Downstream Products

• 1588480-38-9 2-(morpholin-2-yl)acetic acid hydrochloride 
• 1033219-23-6 WYE-114152 
• 1033219-19-0 1-(3-methoxyphenyl)-3-{2-[(2R)-morpholin-2-yl]ethyl}-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1033219-02-1 1-(4-fluorophenyl)-3-{2-[(2R)-morpholin-2-yl]ethyl}-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1033219-08-7 1-(2,4-difluorophenyl)-3-{2-[(2R)-morpholin-2-yl]ethyl}-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1033219-15-6 1-{2-[(2R)-morpholin-2-yl]ethyl}-3-(2,4,6-trifluorophenyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1334315-81-9 4-fluoro-1-(2-fluorophenyl)-3-(2-morpholin-2-ylethyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1334315-83-1 5-fluoro-1-(2-fluorophenyl)-3-(2-morpholin-2-ylethyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1334315-86-4 5-fluoro-3-(2-fluorophenyl)-1-(2-morpholin-2-ylethyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1334315-89-7 4-fluoro-3-(2-fluorophenyl)-1-(2-morpholin-2-ylethyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 913642-78-1 (±)-tert-butyl 2-(2-hydroxyethyl)morpholine-4-carboxylate 
• 1033218-92-6 1-(2-morpholin-2-ylethyl)-3-phenyl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1039033-19-6 C₂₃H₂₉N₃O₅S 
• 132995-76-7 (2-hydroxyethyl)-morpholine 

Relevant articles and documents

Novel anticancer compound and usage thereof

The invention provides a novel anticancer compound. The novel anticancer compound is a compound shown in chemical formula 1 in the description or pharmaceutically acceptable salt of the compound, andthe compound and the salt are active ingredients of a pharmaceutical composition for inhibiting the activity of hepatocyte growth factor receptor (c-Met) tyrosine kinase and pharmaceutical compositionfor preventing or curing excessive or abnormal proliferative diseases. The compound effectively inhibits the activity of the hepatocyte growth factor receptor tyrosine kinase, thereby being suitablefor treating the diseases with the characteristics of excessive or abnormal cell proliferation.

BENZO[B]FURANS AS BROMODOMAIN INHIBITORS

The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.

Substituted morpholine-2S-acetic acid derivatives: SCH 50911 and related compounds as novel GABA(B) antagonists

The synthesis and GABA(B) antagonist activity of a series of substituted morpholine-2-acetic acid derivatives is described. Resolution of the lead compound from the series produces one active and one inactive enantiomer. X- ray analysis of a halogenated derivative (25) of the active enantiomer Sch 50911 (23) shows that it possesses the 2S configuration.